Table 1.
Summary of studies that investigated the circRNAs profile after drug resistance.
| Study | Cancer | Comparison | Differently Expressed circRNA | Expression Alteration | Further Investigation |
|---|---|---|---|---|---|
| [91] | Bladder cancer | T vs. N and cisplatin-resistant vs. naive | hsa_circ_0000285 | ↓ | Prognosis |
| [108] | Prostate cancer | CRPC vs. HSPC | circAR3 | ↓ | Invasion, proliferation, downstream pathways |
| [109] | Prostate cancer | CRPC vs. HSPC | 13 circARs | ↑ | Association with linear AR transcript |
| [137] | Prostate cancer | EnzR vs. naive | 111 circRNAs | NA | NA |
| [139] | Prostate cancer | EnzR vs. naive | circUCK2 | ↓ | Invasion, proliferation |
| [138] | Prostate cancer | EnzR vs. naive | 4 circRNAs | ↑ | |
| 9 circRNAs | ↓ | ||||
| hsa_circ_0047641 | ↑ | Invasion, proliferation |
T = tumor, N = normal, CRPC = castration-resistant prostate cancer, HSPC = hormone sensitive prostate cancer, EnzR = enzalutamide-resistant, NA = not available. The arrows present if the expression of circRNAs elevated (↑) or decreased (↓) in drug-resistant cancers.